953039-66-2 Usage
General Description
7-Bromo-2-chloroquinazoline is a chemical compound with the molecular formula C8H5BrClN2. It is a chloro-substituted quinazoline derivative with a bromine atom attached to the seventh position of the quinazoline ring. 7-Bromo-2-chloroquinazoline has been studied for its potential applications in medicinal chemistry, particularly in the development of pharmaceuticals and agrochemicals. It is known to exhibit biological activity and has been investigated as a potential candidate for the treatment of various diseases. Additionally, it has been used in chemical synthesis and as a building block in the preparation of other organic compounds. Overall, 7-Bromo-2-chloroquinazoline is a versatile chemical with potential applications in various fields including medicine and industrial chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 953039-66-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,3,0,3 and 9 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 953039-66:
(8*9)+(7*5)+(6*3)+(5*0)+(4*3)+(3*9)+(2*6)+(1*6)=182
182 % 10 = 2
So 953039-66-2 is a valid CAS Registry Number.
InChI:InChI=1/C8H4BrClN2/c9-6-2-1-5-4-11-8(10)12-7(5)3-6/h1-4H
953039-66-2Relevant articles and documents
NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
-
Page/Page column 258, (2017/03/14)
The present invention relates novel 6-6 bicyclic aromatic ring substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
QUINAZOLINES FOR PDK1 INHIBITION
-
, (2008/06/13)
The invention provides novel quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.